NLRP3, a potential therapeutic target for type 2 diabetes?

Cardiovasc Drugs Ther. 2014 Aug;28(4):391-2. doi: 10.1007/s10557-014-6531-z.
No abstract available

Publication types

  • Comment

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetic Cardiomyopathies / drug therapy*
  • Fluorobenzenes / pharmacology*
  • Pyrimidines / pharmacology*
  • Receptors, Cytoplasmic and Nuclear / genetics*
  • Sulfonamides / pharmacology*

Substances

  • Fluorobenzenes
  • Pyrimidines
  • Receptors, Cytoplasmic and Nuclear
  • Sulfonamides